U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C3H5N3O9
Molecular Weight 227.0867
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NITROGLYCERIN

SMILES

C(C(CON(=O)=O)ON(=O)=O)ON(=O)=O

InChI

InChIKey=SNIOPGDIGTZGOP-UHFFFAOYSA-N
InChI=1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16103363 | https://www.ncbi.nlm.nih.gov/pubmed/22040938

Nitroglycerin was first invented in 1847 and has been used as an active ingredient in the manufacture of explosives, mostly dynamite. Nitroglycerin came into medical use in 1878 as as a potent vasodilator (dilation of the vascular system) to treat heart conditions, such as angina pectoris and chronic heart failure. Upon administration, nitroglycerin is converted to nitric oxide (NO) by mitochondrial aldehyde dehydrogenase. NO is a potent activator of guanylyl cyclase (GC) by heme-dependent mechanisms.

Originator

Curator's Comment:: Nitroglycerin was first synthesized by the Italian chemist Ascanio Sobrero in 1847, working under Théophile-Jules Pelouze at the University of Turin

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NITROSTAT

Approved Use

Acute relief of angina pectoris secondary to CAD; acute prophylactic management in situations likely to provoke angina attacks; and long-term prophylactic management of angina pectoris.

Launch Date

9.4703039E11
Primary
NITROGLYCERIN

Approved Use

Management of patients with acute myocardial infarction (MI). Nitroglycerin is one of the principal initial therapies of MI.

Launch Date

3.71174408E11
Primary
NITROGLYCERIN

Approved Use

IV nitroglycerin is used to control BP in perioperative hypertension, especially hypertension associated with cardiovascular procedures; to control BP in patients with severe hypertension† or in hypertensive crises for the immediate reduction of BP in patients in whom such reduction is considered an emergency (hypertensive emergencies), especially those associated with coronary complications (e.g., coronary ischemia, acute coronary insufficiency, acute left ventricular failure, postoperative hypertension [especially following coronary bypass surgery]); and to produce controlled hypotension during surgical procedures.

Launch Date

3.71174408E11
Primary
NITROGLYCERIN

Approved Use

IV nitroglycerin has been used in the management of acutely decompensated (e.g., congestive) heart failure and other low cardiac-output states.

Launch Date

3.71174408E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.7 pg/mL
800 μg single, sublingual
dose: 800 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
NITROGLYCERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
84 ng/mL
13 mg single, oral
dose: 13 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLYCERYL 1,2-DINITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12.3 pg × min/mL
800 μg single, sublingual
dose: 800 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
NITROGLYCERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3380 ng × min/mL
13 mg single, oral
dose: 13 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLYCERYL 1,2-DINITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
40 min
800 μg single, sublingual
dose: 800 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
NITROGLYCERIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
50 min
13 mg single, oral
dose: 13 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GLYCERYL 1,2-DINITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1 ug/kg/min multiple, intravenous (starting)
Dose: 1 ug/kg/min
Route: intravenous
Route: multiple
Dose: 1 ug/kg/min
Sources:
pregnant, 26 years
n = 16
Health Status: pregnant
Condition: Preterm labor
Age Group: 26 years
Sex: F
Population Size: 16
Sources:
Disc. AE: Hypotension...
AEs leading to
discontinuation/dose reduction:
Hypotension (4 patients)
Sources:
8 ug/kg/min multiple, intravenous
Dose: 8 ug/kg/min
Route: intravenous
Route: multiple
Dose: 8 ug/kg/min
Sources:
pregnant, 26 years
n = 1
Health Status: pregnant
Condition: Preterm labor
Age Group: 26 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (severe, 1 patient)
Vomiting (severe, 1 patient)
Headache (severe, 1 patient)
Sources:
35 ug/kg/min single, intravenous
Dose: 35 ug/kg/min
Route: intravenous
Route: single
Dose: 35 ug/kg/min
Sources:
unhealthy, 50 years (range: 19 ± 74 years)
n = 105
Health Status: unhealthy
Age Group: 50 years (range: 19 ± 74 years)
Sex: M+F
Population Size: 105
Sources:
Disc. AE: Hemodynamic test abnormal...
AEs leading to
discontinuation/dose reduction:
Hemodynamic test abnormal (8 patients)
Sources:
0.6 mg/h 1 times / day multiple, transdermal
Highest studied dose
Dose: 0.6 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.6 mg/h, 1 times / day
Sources:
unhealthy, 51.4 ±4.3 years
n = 11
Health Status: unhealthy
Condition: menopausal hot flashes
Age Group: 51.4 ±4.3 years
Sex: F
Population Size: 11
Sources:
2 % 6 times / day multiple, topical
Dose: 2 %, 6 times / day
Route: topical
Route: multiple
Dose: 2 %, 6 times / day
Sources:
unhealthy, 57 - 71 years
n = 2
Health Status: unhealthy
Age Group: 57 - 71 years
Sex: M
Population Size: 2
Sources:
Disc. AE: Pruritic rash, Erythema edematous...
AEs leading to
discontinuation/dose reduction:
Pruritic rash (2 patients)
Erythema edematous (2 patients)
Vesicular eruption (2 patients)
Sources:
40 mg single, oral
Overdose
unhealthy, 80 years
n = 1
Health Status: unhealthy
Condition: angina pectoris
Age Group: 80 years
Sex: M
Population Size: 1
Sources:
Other AEs: Methemoglobinemia...
0.2 mg/h 1 times / day multiple, transdermal (starting)
Recommended
Dose: 0.2 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.2 mg/h, 1 times / day
Sources:
unhealthy, adult
n = 307
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 307
Sources:
Other AEs: Headache, Lightheadedness...
Other AEs:
Headache (63%)
Lightheadedness (6%)
Hypotension (4%)
Syncope (4%)
Sources:
1.5 mg 2 times / day multiple, rectal
Dose: 1.5 mg, 2 times / day
Route: rectal
Route: multiple
Dose: 1.5 mg, 2 times / day
Sources:
unhealthy, adult
Disc. AE: Hypotension...
AEs leading to
discontinuation/dose reduction:
Hypotension
Sources:
5 ug/kg 1 times / day single, subcutaneous
Dose: 5 ug/kg, 1 times / day
Route: subcutaneous
Route: single
Dose: 5 ug/kg, 1 times / day
Sources:
unhealthy, pediatric
n = 57
Health Status: unhealthy
Age Group: pediatric
Population Size: 57
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypotension 4 patients
Disc. AE
1 ug/kg/min multiple, intravenous (starting)
Dose: 1 ug/kg/min
Route: intravenous
Route: multiple
Dose: 1 ug/kg/min
Sources:
pregnant, 26 years
n = 16
Health Status: pregnant
Condition: Preterm labor
Age Group: 26 years
Sex: F
Population Size: 16
Sources:
Headache severe, 1 patient
Disc. AE
8 ug/kg/min multiple, intravenous
Dose: 8 ug/kg/min
Route: intravenous
Route: multiple
Dose: 8 ug/kg/min
Sources:
pregnant, 26 years
n = 1
Health Status: pregnant
Condition: Preterm labor
Age Group: 26 years
Sex: F
Population Size: 1
Sources:
Nausea severe, 1 patient
Disc. AE
8 ug/kg/min multiple, intravenous
Dose: 8 ug/kg/min
Route: intravenous
Route: multiple
Dose: 8 ug/kg/min
Sources:
pregnant, 26 years
n = 1
Health Status: pregnant
Condition: Preterm labor
Age Group: 26 years
Sex: F
Population Size: 1
Sources:
Vomiting severe, 1 patient
Disc. AE
8 ug/kg/min multiple, intravenous
Dose: 8 ug/kg/min
Route: intravenous
Route: multiple
Dose: 8 ug/kg/min
Sources:
pregnant, 26 years
n = 1
Health Status: pregnant
Condition: Preterm labor
Age Group: 26 years
Sex: F
Population Size: 1
Sources:
Hemodynamic test abnormal 8 patients
Disc. AE
35 ug/kg/min single, intravenous
Dose: 35 ug/kg/min
Route: intravenous
Route: single
Dose: 35 ug/kg/min
Sources:
unhealthy, 50 years (range: 19 ± 74 years)
n = 105
Health Status: unhealthy
Age Group: 50 years (range: 19 ± 74 years)
Sex: M+F
Population Size: 105
Sources:
Erythema edematous 2 patients
Disc. AE
2 % 6 times / day multiple, topical
Dose: 2 %, 6 times / day
Route: topical
Route: multiple
Dose: 2 %, 6 times / day
Sources:
unhealthy, 57 - 71 years
n = 2
Health Status: unhealthy
Age Group: 57 - 71 years
Sex: M
Population Size: 2
Sources:
Pruritic rash 2 patients
Disc. AE
2 % 6 times / day multiple, topical
Dose: 2 %, 6 times / day
Route: topical
Route: multiple
Dose: 2 %, 6 times / day
Sources:
unhealthy, 57 - 71 years
n = 2
Health Status: unhealthy
Age Group: 57 - 71 years
Sex: M
Population Size: 2
Sources:
Vesicular eruption 2 patients
Disc. AE
2 % 6 times / day multiple, topical
Dose: 2 %, 6 times / day
Route: topical
Route: multiple
Dose: 2 %, 6 times / day
Sources:
unhealthy, 57 - 71 years
n = 2
Health Status: unhealthy
Age Group: 57 - 71 years
Sex: M
Population Size: 2
Sources:
Methemoglobinemia grade 5, 1 patient
40 mg single, oral
Overdose
unhealthy, 80 years
n = 1
Health Status: unhealthy
Condition: angina pectoris
Age Group: 80 years
Sex: M
Population Size: 1
Sources:
Hypotension 4%
0.2 mg/h 1 times / day multiple, transdermal (starting)
Recommended
Dose: 0.2 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.2 mg/h, 1 times / day
Sources:
unhealthy, adult
n = 307
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 307
Sources:
Syncope 4%
0.2 mg/h 1 times / day multiple, transdermal (starting)
Recommended
Dose: 0.2 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.2 mg/h, 1 times / day
Sources:
unhealthy, adult
n = 307
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 307
Sources:
Lightheadedness 6%
0.2 mg/h 1 times / day multiple, transdermal (starting)
Recommended
Dose: 0.2 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.2 mg/h, 1 times / day
Sources:
unhealthy, adult
n = 307
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 307
Sources:
Headache 63%
0.2 mg/h 1 times / day multiple, transdermal (starting)
Recommended
Dose: 0.2 mg/h, 1 times / day
Route: transdermal
Route: multiple
Dose: 0.2 mg/h, 1 times / day
Sources:
unhealthy, adult
n = 307
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 307
Sources:
Hypotension Disc. AE
1.5 mg 2 times / day multiple, rectal
Dose: 1.5 mg, 2 times / day
Route: rectal
Route: multiple
Dose: 1.5 mg, 2 times / day
Sources:
unhealthy, adult
PubMed

PubMed

TitleDatePubMed
[Reactivity of cerebral vessels in patients with circulatory encephalopathy, arterial hypertension and cerebral hypoperfusion risk].
2001
The effect of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure and platelet function in acute stroke.
2001
The use of intravenous nitroglycerin in a case of spasm of the sphincter of Oddi during laparoscopic cholecystectomy.
2001 Apr
Treatment of anal fissure with glyceryl trinitrate in patients referred for surgical management.
2001 Apr
Ultrasound vasography evaluation of radial arterial grafts used for coronary arterial bypass surgery.
2001 Apr
[The effects of milrinone on hemodynamics in patients undergoing cardiac surgery].
2001 Apr
Glyceryl trinitrate and acute uterine relaxation: a literature review.
2001 Apr
Does nitric oxide play a role in the aetiology of pre-eclampsia?
2001 Apr
Nonadrenergic, noncholinergic relaxation of human isolated corpus cavernosum induced by scorpion venom.
2001 Apr
Topical diltiazem ointment in the treatment of chronic anal fissure.
2001 Apr
Effects of nitrovasodilators on the human fetal-placental circulation in vitro.
2001 Apr
Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis.
2001 Apr
S-Transnitrosylation of albumin in human plasma and blood in vitro and in vivo in the rat.
2001 Apr 7
Improved analysis of brachial artery ultrasound using a novel edge-detection software system.
2001 Aug
[Aspirin and nitroglycerine: a good combination for gastric mucosa].
2001 Aug-Sep
Investigations into migraine pathogenesis: time course for effects of m-CPP, BW723C86 or glyceryl trinitrate on appearance of Fos-like immunoreactivity in rat trigeminal nucleus caudalis (TNC).
2001 Feb
Effects of nitric oxide donors on the contractility and prostaglandin synthesis of myometrial strips from pregnant and non-pregnant women.
2001 Feb
Cardiac natriuretic peptides--hope or hype?
2001 Feb
Continued cigarette smoking after coronary artery bypass surgery reduces endothelium-dependent vasodilation in internal thoracic artery grafts.
2001 Feb
NO donors inhibit Leishmania infantum cysteine proteinase activity.
2001 Feb 9
Effects of C-peptide on forearm blood flow and brachial artery dilatation in patients with type 1 diabetes mellitus.
2001 Jul
Different mechanisms of isoproterenol-induced and nitroglycerin-induced syncope during head-up tilt in patients with unexplained syncope: important role of epinephrine in nitroglycerin-induced syncope.
2001 Jul
Gender difference in age-related changes in vascular function.
2001 Jul
Potentiation of sildenafil-induced hypotension is minimal with nitrates generating a radical intermediate.
2001 Jul
Transoesophageal acoustic quantification for evaluation of cardiac function during laparoscopic surgery.
2001 Jul
Pseudonormal diastolic filling unmasked with glyceryl trinitrate in patients with type 2 diabetes with poor metabolic control.
2001 Jul
Reduction of organic nitrates catalysed by xanthine oxidoreductase under anaerobic conditions.
2001 Jul 2
The effect of nitric oxide donors and L-arginine on the gastric electrolyte barrier.
2001 Jun
Long-term outcome of patients with ergonovine induced coronary constriction not associated with ischemic electrocardiographic changes.
2001 Jun
Changes in endothelium-dependent vasodilatation and alpha-adrenergic responses in resistance vessels during the menstrual cycle in healthy women.
2001 Jun
Reasons for failure of glyceryl trinitrate treatment of chronic fissure-in-ano: a multivariate analysis.
2001 Jun
Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles.
2001 Jun
Nitric oxide in primary headaches.
2001 Jun
Ecstasy induced acute myocardial infarction.
2001 Jun
Augmentation of nitric oxide to treat detrusor-external sphincter dyssynergia in spinal cord injury.
2001 Jun 16
Technique for using video microscopy and indicator dilution for repeated measurements of cardiac output in small animals.
2001 Mar
Effect of acute blood pressure reduction on endothelial function in the brachial artery of patients with essential hypertension.
2001 Mar
Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache.
2001 Mar
Comparison of topically applied 0.2% glyceryl trinitrate ointment, incision and excision in the treatment of perianal thrombosis.
2001 May
Audit of topical glyceryl trinitrate for treatment of fissure-in-ano.
2001 May
Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria.
2001 May
Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris.
2001 May
Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure.
2001 May
An update on nesiritide for treatment of decompensated heart failure.
2001 May
Glyceryl trinitrate ointment as a potential treatment for primary vaginismus.
2001 May
Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta.
2001 May 1
Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model.
2001 May 1
[Nitrate headache in blasting work].
2001 May 15
Heart preservation with celsior solution improved by the addition of nitroglycerine.
2001 May 27
Treatment of chronic anal fissure with topical glyceryl trinitrate: a double-blind, placebo-controlled trial.
2001 May-Jun
Patents

Patents

Sample Use Guides

Nitroglycerin in 5% Dextrose Injection is intended for intravenous administration using sterile equipment. It should be administered only via an infusion pump that can maintain a constant infusion rate. For treatment of acute anginal attack, one tablet of Nitrostat should be dissolved under the tongue or in the buccal pouch at the first sign of an acute anginal attack. The dose may be repeated approximately every 5 minutes, until relief is obtained. If the pain persists after a total of 3 tablets in a 15-minute period, or the pain is different than is typically experienced, prompt medical attention is recommended. Nitrostat may be used prophylactically 5 to 10 minutes prior to engaging in activities which might precipitate an acute attack.
Route of Administration: Other
Vasoactivity of nitroglycerin was measured using an ex vivo assay. Mice thoracic aortae were removed, cleaned, and cut into 3-mm rings. Rings were mounted on strain gauge transducers under 1 g of resting tension, and maintained at 37°C in Krebs solution, bubbled continuously with 20% O2/5% CO2/75% N2. Rings were allowed to equilibrate for 1 h before active tension was induced with prostaglandin F2α. Application of Nitroglycerine relieve the F2α-induced strain with IC50 of 10-7 M for wt mice, and 10-5 for mtALDH-/- mice.
Name Type Language
NITROGLYCERIN
HSDB   MI   ORANGE BOOK   USP   VANDF  
Systematic Name English
NITRO-DUR
Brand Name English
GLYCERYL TRINITRATE [WHO-DD]
Common Name English
RECTIV
Brand Name English
NITRO IV
Brand Name English
GLYCERIN TRINITRATE
Systematic Name English
NITROGLYCERIN TABLETS [JAN]
Common Name English
DILUTED NITROGLYCERIN [USP-RS]
Common Name English
NITROGLYCERIN [ORANGE BOOK]
Common Name English
PROPANE-1,2,3-TRIYL TRINITRATE
Systematic Name English
MINITRAN
Brand Name English
GLONOINUM [HPUS]
Common Name English
TRINITRIN
Common Name English
NITROGLYCERIN [MI]
Common Name English
NITORA
Common Name English
NTG
Common Name English
TRINITRINE
Common Name English
NITROGLYCERIN [VANDF]
Common Name English
NITROMIST
Brand Name English
NITRONAL
Brand Name English
NITROL
Brand Name English
GONITRO
Common Name English
GLONOINUM
HPUS  
Common Name English
C01DA02
Code English
NITROLINGUAL
Brand Name English
TRIDIL
Brand Name English
GLYCERYL TRINITRATE
MART.   WHO-DD  
Systematic Name English
NITROSTAT
Brand Name English
DILUTED NITROGLYCERIN [USP MONOGRAPH]
Common Name English
GLYCERYL TRINITRATE [MART.]
Common Name English
TRANSDERM-NITRO
Brand Name English
TRINITROGLYCERIN
Systematic Name English
NITRO-BID
Brand Name English
1,2,3-PROPANETRIOL, TRINITRATE
Systematic Name English
NITROGLYCERIN [USP]
Common Name English
DILUTED NITROGLYCERIN
USP-RS  
Common Name English
GLYCEROL TRINITRATE
Systematic Name English
IMX-150
Common Name English
NITROGLYCERIN [HSDB]
Common Name English
1,2,3-PROPANETRIOL TRINITRATE
Systematic Name English
Classification Tree Code System Code
WHO-VATC QC05AE01
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
WHO-VATC QC01DA02
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
CFR 21 CFR 250.102
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
NDF-RT N0000007647
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
NDF-RT N0000007647
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
EU-Orphan Drug EU/3/15/1435
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
NCI_THESAURUS C29707
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
WHO-ATC C01DA52
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
WHO-ATC C05AE01
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
LIVERTOX 691
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
NDF-RT N0000007647
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
NDF-RT N0000009909
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 12.1
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
WHO-VATC QC01DA52
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
NDF-RT N0000007647
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
NDF-RT N0000175415
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
WHO-ATC C01DA20
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
WHO-ATC C01DA02
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
Code System Code Type Description
ECHA (EC/EINECS)
200-240-8
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
FDA UNII
G59M7S0WS3
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
PUBCHEM
4510
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY
DRUG CENTRAL
1952
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
WIKIPEDIA
NITROGLYCERIN
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY
HSDB
30
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY
EVMPD
SUB11999MIG
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
EPA CompTox
55-63-0
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
NCI_THESAURUS
C29294
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY
IUPHAR
7053
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY
USP_CATALOG
1466506
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY USP-RS
ChEMBL
CHEMBL730
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
MERCK INDEX
M7964
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY Merck Index
DRUG BANK
DB00727
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
LACTMED
Nitroglycerin
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY
EVMPD
SUB13997MIG
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
CAS
55-63-0
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
RXCUI
4917
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY RxNorm
EVMPD
SUB90670
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
PRIMARY
CAS
9010-02-0
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
SUPERSEDED
MESH
D005996
Created by admin on Sat Jun 26 03:15:35 UTC 2021 , Edited by admin on Sat Jun 26 03:15:35 UTC 2021
PRIMARY
EVMPD
SUB96541
Created by admin on Sat Jun 26 03:15:34 UTC 2021 , Edited by admin on Sat Jun 26 03:15:34 UTC 2021
ALTERNATIVE